Okyo Names Robert Dempsey CEO: Leadership Update

By Dr. Helena Fischer - Editor, Health

No Comments

January 7, 2026 7:27 am

Okyo Names Robert Dempsey CEO: Leadership Update

2. Related

Here’s⁢ a breakdown of the provided text, focusing on key facts and structure:

Overall summary:

This‌ article‌ announces the appointment of Robert J. Dempsey as the new CEO of Okyo Pharma. The move is intended to support the company’s advancement of urcosimod, a drug in ‌advancement for neuropathic corneal pain and ocular inflammatory disorders. The previous CEO, Gary S. Jacob, will transition to the role of Chief⁢ Development ⁣Officer.

Key Information:

* New CEO: Robert J. dempsey
* Company: Okyo ⁣Pharma
* Previous CEO: ⁤ Gary S. Jacob (now Chief Development Officer)
* ‍ Drug in Development: urcosimod (formerly OK-101)
* conditions Targeted: Neuropathic corneal pain and ocular inflammatory disorders.
* FDA Status: Urcosimod has received Fast Track designation from the FDA (May 2025).
* Clinical Trial Results: Phase 2 trial showed pain reduction in patients with neuropathic corneal pain.
* Dempsey’s Experience: Over 20 years in global ophthalmology, including‌ leading the launch of Xiidra at‍ Shire.
* Future Focus: Phase 2b study execution‍ and establishing Okyo as a leader in⁣ neuropathic corneal pain‌ treatment.

Article Structure:

Introductory⁣ Paragraphs: Announce the CEO appointment and highlight Dempsey’s experience.
Drug Information: Details about⁢ urcosimod, its development stage,‍ and clinical trial results.
CEO Transition: Explains Gary S. Jacob’s new role.
Quote from Dempsey: Provides‍ insight into his ⁢vision⁢ for the company and the‍ potential impact of urcosimod.
Source/Disclosure: Identifies the source of the information (a press release) and any‌ relevant‍ disclosures (Dempsey’s employment ⁣by‍ Okyo⁣ Pharma).
Healio AI Promotion: An advertisement for Healio’s AI tool.
Footer: Publisher logo.

additional Notes:

* The article includes a figure (image) with a caption ⁣summarizing Dempsey’s experience.
* There are ‌links to related articles on Healio regarding urcosimod’s FDA designation and phase 2 trial‍ results.
* The HTML includes some code related to a modal window for‍ error‌ messages (likely a technical ⁤element for the website).

Also Read: Yellowstone National Park Quiz: Test Your Knowledge!

Dr. Helena Fischer - Editor, Health

Full Name: Dr. Helena Fischer Role: Editor, Health Category: Health Location: Berlin, Germany Education: MD, Charité – Universitätsmedizin Berlin Experience: 11+ years in medical journalism and internal medicine Expertise: Public health, infectious diseases, healthcare policy, medical innovation Awards: European Health Journalism Award 2023 Professional Affiliations: Member, European Association of Science Editors Languages: German (native), English (fluent), Spanish (conversational) Bio: Dr. Helena Fischer is a respected physician and health journalist with over a decade of experience in internal medicine and science communication. She holds an MD from Charité – Universitätsmedizin Berlin. Dr. Fischer is passionate about public health, medical innovation, and making complex medical topics accessible to all. As Editor of the Health section at World Today Journal, she is dedicated to providing readers with accurate, up-to-date health news and expert analysis.